Weiguo Qing

1.4k citations

22 papers · 802 indexed · 1 hit paper · h-index 8

Impact in

Oncology top 10%
- Cancer-related Molecular Pathways
Hepatology top 10%
- Liver physiology and pathology

Papers in

Hepatology 9
- Liver physiology and pathology 8
- Hepatocellular Carcinoma Treatment and Prognosis 4
Oncology 10
- Colorectal Cancer Treatments and Studies 2

Co-authors: Holly Hilton Kenneth Kolinsky James Rosinski Lyubomir T. Vassilev Ola Myklebost Binh Thanh Vu Kathryn Packman Christian Tovar
Journals: Cancer Research (9 papers)Molecular Cancer Therapeutics (2 papers)Oncotarget (2 papers)European Journal of Pharmaceutical Sciences (1 paper)Toxicology (1 paper)
Partner nations: United States China Switzerland

In The Last Decade

Weiguo Qing

22 papers receiving 794 citations

Hit Papers

align trajectories log scale

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy 2006 · 553 citations

Peers

Countries citing papers authored by Weiguo Qing

Since Specialization

Citations

This map shows the geographic impact of Weiguo Qing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiguo Qing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiguo Qing more than expected).

Fields of papers citing papers by Weiguo Qing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weiguo Qing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiguo Qing. The network helps show where Weiguo Qing may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Weiguo Qing, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Weiguo Qing Line = papers co-authored together Weiguo Qing links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Abstract 2113: HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearrangedand NPM1mutant acute leukemia in preclinical models Cancer Research ·Min Cheng, Liang Ge, Khair Ahmed Choudhury, Zeyu Zhong, Ajay Nayak Gugulothu, Łukasz Iwanczewski, L. Allegretti, Shuwen Jiang, Na Li, Na Yang, Jian Wang, Agatha Nwankpa, Weiguo Qing, Yongxin Ren, Weiguo Su	2024	1
2	Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies Cancer Research ·Linfang Wang, E.D. Pounentis, Khair Ahmed Choudhury, Jia Hu, Amit Bhattacharyya, Xian‐Wen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, 正石本, Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su	2023	1
3	Abstract C160: HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment Molecular Cancer Therapeutics ·Jia Hu, Liang Ge, Hui Zhang, An Jiang, Luz Marina Lizarazo Forero, Hans Meiser, Jian Wang, John R. Clark, Na Yang, Weiguo Qing, Yongxin Ren, Michael Shi, Weiguo Su	2023	2
4	Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma. PubMed ·Tanya Bomsta, DED, Qian Peng, J BROCK, Mara Cibelly da Silva Pinheiro, Xuan Zeng, Weiguo Qing, Yi Wu	2023	2
5	Abstract 543: Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2 Cancer Research ·Na Yang, Jia Hu, Tingwen Li, Luz Marina Lizarazo Forero, Dongxia Shi, Min Cheng, Zeyu Zhong, Jian Wang, Kathleen Tailer, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su	2023	3
6	Abstract 5454: Amdizalisib (HMPL-689), a highly selective PI3Kδ inhibitor, exhibits potent anti-tumor activity in pre-clinical B-cell lymphoma models Cancer Research ·Jia Hu, Варвара Васильевна Сидоренко, Xiaoming Dai, Abdulhamit Türk, E.D. Pounentis, Ying Yu, Luz Marina Lizarazo Forero, Na Yang, Linfang Wang, Fadel Bimawanpati, Li Xiong, Weiguo Qing, Yongxin Ren, Weiguo Su	2022	3
7	Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor European Journal of Pharmaceutical Sciences ·Yi Gu, Yang Sai, Jian Wang, Diana Arellano, Guanglin Wang, Li Zhang, Hong‐Can Ren, Shiming Fan, Yongxin Ren, Weiguo Qing, Weiguo Su	2019	16
8	Abstract 2089: Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Cancer Research ·Yongxin Ren, Qiaoling Sun, Flight Systems, Shiming Fan, Jadwiga Tarsa, Wei Zhang, A. Zofajova, Shuichi Tsuchida, Linfang Wang, Dmitriy V. Bondarev, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su	2017	6
9	Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification Oncotarget ·Yongxin Ren, Jianming Zheng, Shiming Fan, Linfang Wang, Min Cheng, Dmitriy V. Bondarev, Wei Zhang, Jadwiga Tarsa, Yingyan Yu, 敦小野寺, Jun Ni, Jennifer M. Cartony, 童珏, GERTRUD GOETZE, Yunxin Chen, Feng Zhou, Weihan Zhang, Weiguo Qing, Weiguo Su	2017	3
10	HMPL-523, a Novel SYK Inhibitor Showed Anti-Tumor Activities In Vitro and In Vivo Blood ·Yang Na, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Jadwiga Tarsa, Ying Yu, Daylín Rodríguez Javiqué, Feng Zhou, Guangxiu Dai, Weiguo Qing, Wei-guo Su, Yongxin Ren	2016	1
11	Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation Oncotarget ·Ryan E. Henry, Evan Barry, Lillian Castriotta, Brendon Ladd, Aleksandra Markovets, Garry Beran, Yongxin Ren, Feng Zhou, Ammar Adam, Michael Zinda, Corinne Reimer, Weiguo Qing, Weiguo Su, Edwin Clark, Celina M. D’Cruz, Alwin G. Schuller	2016	27
12	Abstract B189: Synergistic effect of c-Met inhibitor savolitinib in combination with a VEGFR inhibitor fruquintinib in clear cell renal cell carcinoma xenograft models Molecular Cancer Therapeutics ·Yongxin Ren, Shiming Fan, Yunxin Chen, Jadwiga Tarsa, Wei Zhang, Shuichi Tsuchida, Linfang Wang, Dmitriy V. Bondarev, Hongbo Chen, Min Cheng, Weiguo Qing, Weiguo Su	2015	1
13	Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer Journal of Medicinal Chemistry ·Olivia A. MARCU, Guangxiu Dai, H.Nietbaeva, J. A. Lopes da Silva, Qing Wang, Feng Zhou, 敦小野寺, Yumin Cui, Yongxin Ren, Shiming Fan, Jinghong Zhou, Weiguo Qing, Yi Gu, Jian Wang, Yang Sai, Weiguo Su	2014	111
14	Abstract 928: Volitinib (HMPL504), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer. Cancer Research ·Paul R. Gavine, Shiming Fan, Haihua Fu, Lu Han, مهرانه خدامرادپور, Jing Lv, Weiguo Qing, Yongxin Ren, Weiguo Su, Xinying Su, Huiying Wang, Liang Xie, Hiromi Arima, Wen Xu, Xiaolu Yin, 一也米山, Tianwei Zhang, Hans–Günter Semsek	2013	2
15	Abstract 971: Synergistic effect of c-Met inhibitor volitinib in combination with EGFR inhibitor Gefitnib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification. Cancer Research ·Feng Zhou, Yongxin Ren, Yumin Cui, Hanyang Chen, 敦小野寺, Guangxiu Dai, Shiming Fan, Daylín Rodríguez Javiqué, 一也米山, Yang Sai, Yi Gu, Weiguo Qing, Weiguo Su	2013	4
16	Identification of novel, potent and selective inhibitors of Polo-like kinase 1 Bioorganic & Medicinal Chemistry Letters ·Shaoqing Chen, David Bartkovitz, Jianping Cai, Yi Chen, Zhi Chen, Angela Phung, Duval Alexander Caicedo Cárdenas, Inssaf Ammari, Kin‐Chun Luk, Christophe Falin, 憲一香月, John F. Boylan, 王澤惠, Weiguo Qing, Yingsi Chen, Peter M. Wovkulich	2011	22
17	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Proceedings of the National Academy of Sciences ·Christian Tovar, James Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu, Weiguo Qing, Kathryn Packman, Ola Myklebost, David Heimbrook, Lyubomir T. Vassilev Hit paper breakdown →	2006	553
18	Mixed effects of 2,6-dithiopurine against cyclophosphamide mediated bladder and lung toxicity in mice Toxicology ·Kaushik Datta, Seong Chae Park, Doç. Dr. Gökhan DEMİRCİOĞLU, Weiguo Qing, Katherine Powell, Joaquin De Carlos-Errea, Michael C. MacLeod, George Stoica, James P. Kehrer	1998	12
19	Kinetics of the Reaction of a Potential Chemopreventive Agent, 2,6-Dithiopurine, and Its Major Metabolite, 2,6-Dithiouric Acid, with Multiple Classes of Electrophilic Toxicants Chemical Research in Toxicology ·Weiguo Qing, Katherine Powell, Michael C. MacLeod	1996	13
20	Toxicity and metabolism in mice of 2,6-dithiopurine, a potential chemopreventive agent. Drug Metabolism and Disposition ·Weiguo Qing, Katherine Powell, George Stoica, C. L. Szumlanski, R. M. Weinshilboum, Michael C. MacLeod	1995	8

About Weiguo Qing

Weiguo Qing is a scholar working on Hepatology, Oncology, Genetics, Pathology and Forensic Medicine and Cancer Research, having authored 22 papers that have together received 802 indexed citations. Recurring topics across this work include Liver physiology and pathology (8 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Chronic Lymphocytic Leukemia Research (3 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Lung Cancer Treatments and Mutations (3 papers), Cancer, Hypoxia, and Metabolism (2 papers), Cancer Mechanisms and Therapy (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Oncology (440 citations), Hepatology (67 citations), Biotechnology (72 citations), Molecular Biology (545 citations) and Cancer Research (113 citations). Weiguo Qing has collaborated with scholars based in United States, China and Switzerland. Frequent co-authors include Holly Hilton, Kenneth Kolinsky, James Rosinski, Lyubomir T. Vassilev, Ola Myklebost, Binh Thanh Vu, Kathryn Packman, Christian Tovar, Xiaolan Zhao and Brian Higgins. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Oncotarget, European Journal of Pharmaceutical Sciences and Toxicology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact